Interleukin 17, the double-edged sword in atherosclerosis.

Area of Science:

• Immunology
• Cardiovascular Medicine
• Inflammation Research

Background:

• Cardiovascular diseases, particularly atherosclerosis, are the leading cause of mortality worldwide.
• Atherosclerosis is recognized as an inflammatory condition where immune cells and signaling molecules play a crucial role in its development.
• Interleukin-17 (IL-17), a recently identified signaling molecule, is implicated in the pathogenesis of atherosclerosis.

Purpose of the Study:

• To review the immunological underpinnings of atherosclerosis.
• To emphasize the specific role of IL-17 in the context of atherosclerosis.
• To briefly explain the impact of IL-17 on atherosclerotic disorders.

Main Methods:

• Literature review focusing on immunological aspects of atherosclerosis.
• Analysis of studies investigating the function of IL-17 in cardiovascular disease.
• Synthesis of current understanding regarding IL-17's pro- and anti-atherogenic effects.

Main Results:

• IL-17 exhibits a complex, potentially dual role in atherosclerosis, acting as both a pro-atherogenic and anti-atherogenic factor.
• Evidence suggests IL-17 is a significant mediator in the inflammatory processes underlying atherosclerosis.
• The dual nature of IL-17 necessitates careful consideration for therapeutic strategies.

Conclusions:

• IL-17 is a key immunological player in atherosclerosis.
• Understanding IL-17's multifaceted role is crucial for developing targeted treatments.
• IL-17 represents a promising, yet complex, target for managing atherosclerosis and related cardiovascular diseases.